Dianthus Therapeutics annual free cash flow
2016
2017
2018
2019
2020
2021
2022
Dianthus Therapeutics Free Cash Flow (FCF) History (DNTH)
Dianthus Therapeutics reported −$29.4M in free cash flow for fiscal 2022, an increase of $31.4M from the previous fiscal year.
View full Dianthus Therapeutics company overviewDianthus Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2022 | 2022-12-31 | −$29.4M | $31.4M | — | — |
| 2021 | 2021-12-31 | −$60.8M | $3.6M | — | — |
| 2020 | 2020-12-31 | −$64.4M | −$4.3M | — | — |
| 2019 | 2019-12-31 | −$60.2M | −$10.6M | — | — |
| 2018 | 2018-12-31 | −$49.6M | −$25.1M | — | — |
| 2017 | 2017-12-31 | −$24.5M | −$17.8M | — | — |
| 2016 | 2016-12-31 | −$6.7M | — | — | — |
Dianthus Therapeutics quarterly free cash flow
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2023 | 2023-06-30 | −$4.7M | $12.3M | — | — |
| Q1 2023 | 2023-03-31 | −$10.5M | $9.2M | — | — |
| Q4 2022 | 2022-12-31 | −$8.9M | $6.9M | — | — |
| Q3 2022 | 2022-09-30 | $16.2M | $31.4M | — | +1382.52% |
| Q2 2022 | 2022-06-30 | −$17.0M | −$3.9M | — | — |
| Q1 2022 | 2022-03-31 | −$19.8M | −$3.0M | — | — |
| Q4 2021 | 2021-12-31 | −$15.7M | −$1.8M | — | — |
| Q3 2021 | 2021-09-30 | −$15.2M | −$750,000 | — | — |
| Q2 2021 | 2021-06-30 | −$13.1M | $6.1M | — | — |
| Q1 2021 | 2021-03-31 | −$16.8M | $7,000 | — | — |
| Q4 2020 | 2020-12-31 | −$13.9M | $1.8M | — | — |
| Q3 2020 | 2020-09-30 | −$14.4M | −$2.4M | — | — |
| Q2 2020 | 2020-06-30 | −$19.2M | −$3.1M | — | — |
| Q1 2020 | 2020-03-31 | −$16.8M | −$601,000 | — | — |
| Q4 2019 | 2019-12-31 | −$15.8M | $1.2M | — | — |
| Q3 2019 | 2019-09-30 | −$12.0M | $987,000 | — | — |
| Q2 2019 | 2019-06-30 | −$16.2M | −$6.4M | — | — |
| Q1 2019 | 2019-03-31 | −$16.2M | −$6.4M | — | — |
| Q4 2018 | 2018-12-31 | −$17.0M | −$11.1M | — | — |
| Q3 2018 | 2018-09-30 | −$13.0M | — | — | — |
| Q2 2018 | 2018-06-30 | −$9.8M | — | — | — |
| Q1 2018 | 2018-03-31 | −$9.8M | — | — | — |
| Q3 2017 | 2017-09-30 | −$5.8M | — | — | — |
Dianthus Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$24.5M to −$29.4M, a net decrease of $4.9M. Dianthus Therapeutics's latest reported quarter, Q2 2023, generated −$4.7M in free cash flow, an increase of $12.3M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Dianthus Therapeutics filings at SEC.gov ↗